EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength

New indication concerns a monotherapy in paediatric patients with CP-CML who are resistant or intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate or who have the T315I mutation

Source